Skip to main content

Healthcare Value Capital, LLC

SEC CIK
0001458461
Latest filing
Nov 15, 2021

The latest 13F from Healthcare Value Capital, LLC covers Q3 2021 (filed Nov 15, 2021): 18 long positions worth $38.5M. The top 10 holdings make up 80.9% of the portfolio, and the largest is Gilead Sciences, Inc. (GILD) at 10.9%. Livermore has 3 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2021

Share counts compared with Q2 2021: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
2
Est. +$1.23M
Added
3
Est. +$1.22M
Reduced
4
Est. −$3.73M
Sold out
2
Est. −$3.93M

Top 5 holdings

Share of this quarter's portfolio value

  1. GILDGilead Sciences, Inc.
    10.9%$4.19MHistory
  2. GSKGSK plc
    9.9%$3.82MHistory
  3. PFEPfizer Inc
    8.4%$3.23MHistory
  4. ALKSAlkermes plc.
    8.0%$3.08MHistory
  5. Amryt Pharma PLC03217L106
    7.8%$3.02M

Share of portfolio

Top 5 holdings and the other 13 positions, by share of portfolio value

  1. GILD10.9%
  2. GSK9.9%
  3. PFE8.4%
  4. ALKS8.0%
  5. Amryt Pharma PLC7.8%
  6. Other 13 positions55.0%

Biggest buys

New and added positions, by estimated amount bought

  1. VRTXVertex Pharmaceuticals Inc
    +$907.0KNewHistory
  2. Amryt Pharma PLC03217L106
    +$604.6KAdded
  3. TYMETyme Technologies, Inc.
    +$515.0KAddedHistory
  4. DRRXDurect Corp
    +$320.0KNewHistory
  5. GMDAGamida Cell Ltd.
    +$98.0KAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. Amryt Pharma PLC03217L106
    +2.60 pp5.2% → 7.8%
  2. VRTXVertex Pharmaceuticals Inc
    +2.35 pp0.0% → 2.4%History
  3. TYMETyme Technologies, Inc.
    +1.26 pp4.1% → 5.3%History
  4. DRRXDurect Corp
    +0.83 pp0.0% → 0.8%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. COLLCollegium Pharmaceutical, Inc
    −$2.36MSold outHistory
  2. MDXGMimedx Group, Inc.
    −$1.56MSold outHistory
  3. ALKSAlkermes plc.
    −$1.54MReducedHistory
  4. PFEPfizer Inc
    −$1.08MReducedHistory
  5. GILDGilead Sciences, Inc.
    −$1.05MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. COLLCollegium Pharmaceutical, Inc
    −5.11 pp5.1% → 0.0%History
  2. MDXGMimedx Group, Inc.
    −3.38 pp3.4% → 0.0%History
  3. YARWYarrow Bioscience, Inc.
    −1.97 pp3.4% → 1.4%History
  4. GILDGilead Sciences, Inc.
    −0.29 pp11.2% → 10.9%History
  5. PFEPfizer Inc
    −0.10 pp8.5% → 8.4%History

Metrics

13F metrics for Q3 2021, computed only from the numbers in the filings. Definitions below.

Portfolio value
$38.5M
−$7.71M (−16.7%) vs. prior quarter
Positions
18
0 vs. prior quarter
Top 10 concentration
80.9%
Top 10 as share of value
Turnover
5.8%
Q3 2021, one quarter
Average holding period
2.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

3 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $46.2M (Q2 2021)

Q1 2021: $39.2MQ2 2021: $46.2MQ3 2021: $38.5M
Q1 2021Q3 2021
13F filings of Healthcare Value Capital, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2021Nov 15, 202118$38.5MGILDGSKPFEvs. Q2 2021SEC
Q2 2021Aug 16, 202118$46.2MGILDGSKPFEvs. Q1 2021SEC
Q1 2021May 17, 202118$39.2MGILDPFEGSK–SEC